Drug Profile
Research programme: viral and bacterial infections therapeutics - Starpharma
Alternative Names: Angiogenesis inhibitor research programme - Starpharma Pooled Developments; Second-generation dendrimers research programme - Starpharma Pooled Developments; Topical microbicides research programme - Starpharma Pooled DevelopmentsLatest Information Update: 29 Mar 2008
Price :
$50
*
At a glance
- Originator Biomolecular Research Institute
- Developer Starpharma
- Class Dendrimers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Hepatitis B; Respiratory tract infections; Sexually transmitted infections; Viral infections
Most Recent Events
- 06 Oct 2006 Preclinical trials in Hepatitis B in Australia (unspecified route)
- 06 Oct 2006 Preclinical trials in Respiratory tract infections in Australia (unspecified route)
- 31 May 2004 Preclinical trials in Venereal infections in Australia (Topical)